NCT05066646: Phase 1/2: A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in RRMM
NCT04808037: Phase 1/2: Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM (BelaRd)
NCT04557098: Phase 2- Teclistamab, in Participants With Relapsed or Refractory Myeloma (MajesTEC-1)
NCT04557150: Phase 1: Safety and Pharmacokinetics of Escalating Doses of RO7425781 RRMM Myeloma
NCT04236011: Phase 1: BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Myeloma
NCT04133636: Phase 2 - Study of JNJ-68284528, CAR-T Therapy Directed Against BCMA in MM -CARTITUDE-2
NCT04108195: Phase 1b - Subcutaneous Dara With Bispecific T Cell Redirection Antibodies - TRIMM-2
NCT03761108: Phase 1/2 - REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Refractory MM
NCT03606577: Phase 2-IFM 2018 - 04 - Quadruplet Induction & Consolidation + Tandem ASCT Hi Risk NDMM
NCT03399799: Phase 1 - Talquetamab, a Humanized GPRC5D x CD3 Bis Ab - Ref MM - MonumenTAL-1
NCT03145181: Phase 1 - Teclistamab, Humanized BCMA*CD3 Bispecific Ab, in Relapsed Myeloma MajesTEC1
NCT03215030: Phase 1/2: Safety, Tolerability, Efficacy, Pharmacok. Immunogenicity of TAK-573 in RRMM
NCT02659293: Phase 3 - ATLAS Trial: Carfilzomib, Lenalidomide & Dex Vs Lenalidomide Alone After ASCT
NCT02891811: Phase 2: Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction